



















Tong et al.

**Writing, review, and/or revision of the manuscript:** J.H. Tong, S.F. Yeung, A.W.H. Chan, T.S.K. Mok, K.F. To

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** J.H. Tong, L.Y. Chung, S.L. Chau, E.K.Y. Tin, R.W. M. Lung, C.Y. Tong, C. Chow, Y.H. Yu, H. Li, Y. Pan, W.P. Chak, C.S.H. Ng, T.S.K. Mok, K.F. To

**Study supervision:** J.H. Tong, R.W.M. Lung, K.F. To

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 25, 2015; revised January 11, 2016; accepted January 16, 2016; published OnlineFirst February 4, 2016.

## References

1. The Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–50.
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol* 2011;12:175–80.
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003;4:915–25.
4. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. *Cancer Res* 2007;67:2081–8.
5. Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. *Lung Cancer* 2014;83:109–11.
6. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *J Thorac Oncol* 2011;6:942–6.
7. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. *Cancer Res* 2006;66:283–9.
8. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. *J Thorac Oncol* 2009;4:5–11.
9. Paik PK, Drilon A, Fan PD, Yu H, Rekhman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. *Cancer Discov* 2015;5:842–9.
10. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 8000).
11. Yeung SF, Tong JH, Law PP, Chung LY, Lung RW, Tong CY, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. *J Thorac Oncol* 2015;10:1292–300.
12. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. *J Thorac Oncol* 2012;7:340–7.
13. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. *J Clin Oncol* 2009;27:1667–74.
14. Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. *Lung Cancer* 2012;75:89–94.
15. Jurmeister P, Lenze D, Berg E, Mende S, Schaper F, Kellner U, et al. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. *Lung Cancer* 2015;87:122–9.
16. Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. *J Thorac Oncol* 2012;7:331–9.
17. Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. *J Thorac Oncol* 2015;10:e29–31.
18. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107–20.
19. Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. *Clin Lung Cancer* 2015;16:E101–4.
20. Azzato EM, Desphande C, Gabriel C, Langer C, Evans T, Gault CR, et al. MET mutations in non-small cell lung cancer: four case reports of mutations at or near the splice junction for exon 14. *J OncoPathol* 2014;2:65.
21. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. *Genome Res* 2012;22:2109–19.
22. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. *Cancer Sci* 2008;99:2280–5.
23. Schildhaus HU, Schultheis AM, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. *Clin Cancer Res* 2015;21:907–15.
24. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. *PLoS One* 2009;4:e7464.
25. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. *Biochem Biophys Res Commun* 2010;394:1042–6.
26. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. *Nat Genet* 2005;37:590–2.
27. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. *J Clin Oncol*. 2015 Jul 27. [Epub ahead of print].
28. Huang SY, Shen SJ, Li XY. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. *World J Surg Oncol* 2013;11:252.
29. Franks TJ, Galvin JR. Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. *Arch Pathol Lab Med* 2010;134:49–54.
30. Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. *Int J Surg Pathol* 2010;18:103–20.
31. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. *Nat Rev Cancer* 2012;12:89–103.
32. Perol M. Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC. *Transl Lung Cancer Res* 2014;3:392–4.
33. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. *Ther Adv Med Oncol* 2011;3:S7–19.

# Clinical Cancer Research

## ***MET* Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non –Small Cell Lung Carcinoma with Poor Prognosis**

Joanna H. Tong, Sai F. Yeung, Anthony W.H. Chan, et al.

*Clin Cancer Res* 2016;22:3048-3056. Published OnlineFirst February 4, 2016.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1078-0432.CCR-15-2061](https://doi.org/10.1158/1078-0432.CCR-15-2061)

**Supplementary Material** Access the most recent supplemental material at:  
<http://clincancerres.aacrjournals.org/content/suppl/2016/02/04/1078-0432.CCR-15-2061.DC1>

**Cited articles** This article cites 32 articles, 6 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/22/12/3048.full#ref-list-1>

**Citing articles** This article has been cited by 11 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/22/12/3048.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/22/12/3048>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.